![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.businesswire.com/news/home/20211115005201/en/NiKang-Therapeutics-Announces-First-Patient-Dosed-in-A-Phase-12-Study-Evaluating-NKT2152-a-Small-Molecule-that-Inhibits-Hypoxia-Inducible-Factor-2%CE%B1-HIF2%CE%B1-for-the-Treatment-of-Advanced-Clear-Cell-Renal-Cell-Carcinoma